tbuckley/cabot-search huggingface dataset:
Parent and child experience of skin conditions: relevance for the provision of mindfulness-based interventions
Authors: Olivia Hughes, Katherine H Shelton, Helen Penny, Andrew R Thompson
Journal: British Journal of Dermatology (2022)

Managing a skin condition can be difficult, and there is a lack of psychological support for children and their families.To identify issues surrounding caring for a child with a skin condition, investigate experiences of current psychological support to gain a sense of what is needed, and determine the relevance of offering mindfulness-based interventions for children and families.This study employed a mixed inductive and deductive form of qualitative inquiry to understand the experiences and needs of children and families. Twenty-three participants (12 parents/carers: 11 females, 1 male; 11 children: 6 females, 5 males, aged 8-11 years) were recruited with an advert posted on social media. In-depth data were collected from semi-structured interviews. Interviews were recorded, transcribed and analysed with a descriptive form of thematic analysis.Systematic analysis of the data led to five themes being developed: (i) caregiver burden of childhood skin conditions; (ii) skin condition overshadowing childhood; (iii) battling for recognition and lack of support; (iv) naturalistic use and understanding of mindfulness in everyday coping: and (v) openness and relevance of offering mindfulness-based interventions.Living with a skin condition was reported as being associated with mood disturbance, with impacts on schooling, sleep and daily life. Parents and children expressed a desire for short/accessible interventions that could fit with daily routines and might provide the opportunity to connect with other families. The findings indicate that mindfulness-based interventions may be likely to be accepted, as many participants had experience of using mindful techniques in school, and described that they were naturalistically using 'mindfulness' to manage itch and stress. However, the findings indicate that a number of misconceptions exist about the fundamental nature and aims of mindfulness. Addressing misconceptions related to mindfulness needs to be considered when planning both future studies and service delivery.
The association of anxiety with granuloma annulare: a case–control study of the National Institutes of Health ‘All of Us’ research programme
Authors: Annika Belzer, Audrey C Leasure, William Damsky, Jeffrey M Cohen
Journal: British Journal of Dermatology (2022)

Dear Editor, Granuloma annulare (GA) is an inflammatory skin disease that has been associated with diabetes, dyslipidaemia, hypothyroidism and autoimmune disorders.1,2 The annualized incidence and prevalence of GA in the USA are approximately 0.04% and 0.06%, respectively (with a female predominance).3 GA is clinically classified as localized (75% of cases), generalized or subcutaneous.4 There is a body of evidence supporting an association between several inflammatory dermatoses, such as psoriasis, and mental health conditions.5 Improvement of depression and anxiety following treatment of certain inflammatory dermatoses has also been described.5 It has been postulated that this association may, in part, relate to proinflammatory cytokines, which have been proposed to mechanistically connect inflammatory dermatoses and mental health conditions.6 A recent nested case-control study demonstrated a significant association of GA with depression, insomnia, opioid dependence and post-traumatic stress disorder.7 This study aims to investigate whether an association exists between GA and anxiety.
An ostomy baseplate with a skin-protection technology reduces peristomal skin complications: a randomized controlled trial (the ATTRACT study)
Authors: Ragne Sætre, Johanne L Gotfredsen, Pernille Nonboe, Helle Doré Hansen, Ronja Mathiesen, Tonny Karlsmark, Zenia M Størling, Thomas Rolfsen
Journal: British Journal of Dermatology (2022)

Abstract Background Peristomal skin complications (PSCs) are the predominant complication for people living with a stoma, negatively affecting their health-related quality of life (HRQoL). PSCs may also have an impact on healthcare costs for society with more visits to healthcare professionals and increased consumption of products and treatment strategies, which amplifies the need for new strategies to reduce or prevent PSCs. Objectives To evaluate the performance of an ostomy baseplate with a skin-protection technology. The target group comprised people living with a stoma with liquid faecal effluent, who struggled with PSCs. Methods A randomized, controlled, open-labelled, cross-over trial was conducted from September 2021 to February 2022 in five different countries. Each participant tested the investigational product against a comparator product (SenSura® Mio). The Ostomy Skin Tool 2.0 was used to evaluate the peristomal skin and HRQoL was measured using the Dermatology Life Quality Index (DLQI) questionnaire. Data were analysed in mixed repeated-measures models. Results A total of 79 adult participants (mean age 54.5 years, female 45.6%) were included in the intention-to-treat (ITT) population. A significant reduction in PSCs (P = 0.015) and HRQoL (P = 0.035) was found for the investigational product when compared with the comparator product. Also, significantly more study participants preferred the investigational product when compared with the comparator product (P = 0.017). Conclusions The investigational product, an ostomy baseplate with a skin-protective technology, reduced PSCs and improved the HRQoL of people living with a stoma with liquid faecal effluent. Consequently, the investigational product was the preferred ostomy appliance of the participants. Thus, the product investigated in this study may be a new solution to be included in everyday clinical practice to overcome leakage-induced PSCs for people living with a stoma.
Analysis of laser-generated plume concentration during <i>in vivo</i> laser hair reduction procedures in a tertiary referral laser dermatology unit
Authors: Lewis C R Jones, Jason Britton, Audrey McCartney, Paula Kipling-Steels, Rachel Urwin, Daniel Lloyd, John R Tyrer
Journal: British Journal of Dermatology (2022)

Air particulate concentrations for a typical day of laser hair reduction procedures in a tertiary referral laser dermatology unit were measured, while all standard operating procedures were followed. Concentrations above the World Health Organisation PM2.5 Air Quality Guidance level were detected even following current guidance on room ventilation and local exhaust ventilation. This suggests that further analysis into this hazard is required to assess the use of current engineering and personal protective equipment controls for operators
Commercial visible-light protecting sunscreens for photosensitive individuals
Authors: Ewan Eadie, Martin Josso, Rita Touti, Pascale Renoux, Robert S Dawe, Sally H Ibbotson
Journal: British Journal of Dermatology (2022)

Visible light sensitivity can have a severe adverse impact on quality of life leading to withdrawal from social activity during daylight hours. Treatment options are limited and expensive. Commercially available sunscreens that provide visible light protection is of immediate practical importance, particularly for patients with Erythropoietic Protoporphyria (EPP) and Solar Urticaria as they experience intense symptoms of pain, burning, itch and urticarial rash or phototoxic erythema within seconds to minutes of even minor VL exposure.
Inguinal patch in mpox (monkeypox) virus infection and eccrine syringometaplasia: report of two cases with <i>in situ</i> hybridization and electron microscopy findings
Authors: Simon F Roy, Joseph Sarhan, Xinran Liu, Michael J Murphy, Christopher G Bunick, Keith A Choate, William B Damsky, Jennifer M McNiff
Journal: British Journal of Dermatology (2022)

We report two cases of cutaneous mpox virus infection (formerly known as monkeypox), one of which presented with unusual clinical findings, and demonstrate their histopathological, RNA in situ hybridization (ISH) and ultrastructural characteristics. We observed in two patients with polymerase chain reaction-confirmed mpox virus infection squamous syringometaplasia of the eccrine ducts, a finding that can aid in recognizing this disease and is explained by the demonstration of viral mRNA within eccrine epithelium by ISH.
How we treat atopic dermatitis now and how that will change over the next 5 years
Authors: Carsten Flohr
Journal: British Journal of Dermatology (2022)

We live in exciting times in atopic dermatitis therapeutics, with many novel treatments in the clinical trial pipeline. Frustratingly, most of these trials are vehicle- or placebo-controlled, rather than head-to-head comparisons. Network meta-analyses can rank treatments against each other, even for placebo-controlled studies, aiding evidence-based guideline formulation and clinical decision-making. Treatment registries are an important additional vehicle to collect 'real-world' data on the long-term (cost) effectiveness and safety of the new drugs, outside of the stringent and short-term settings of clinical trials. As further agents enter clinical practice, the need for biomarkers of treatment response and drug safety becomes more pressing to move us towards personalized medicine and to avoid wasting healthcare resources. This review takes stock of our current treatment armamentarium for atopic dermatitis, highlights important gaps in our knowledge - including the relatively low number of studies conducted in children - and maps out how our treatment approaches for atopic dermatitis can become more targeted and holistic in the future.
Dapsone therapy for hidradenitis suppurativa: a retrospective review of characteristics and treatment outcomes in a cohort of 122 patients in a tertiary dermatology setting
Authors: Mia Steyn, Salma Ayis, Jane O’Connor, Manpreet Kaur Lakhan, Felicity Ferguson, Aadarsh Shah, Ellie Rashidghamat
Journal: British Journal of Dermatology (2022)
‘Eczema shouldn’t control you; you should control eczema’: qualitative process evaluation of online behavioural interventions to support young people and parents/carers of children with eczema
Authors: Kate Greenwell, Katy Sivyer, Laura Howells, Mary Steele, Matthew J Ridd, Amanda Roberts, Amina Ahmed, Sandra Lawton, Sinéad M Langan, Julie Hooper, Sylvia Wilczynska, Paul Leighton, Gareth Griffiths, Tracey Sach, Paul Little, Hywel C Williams, Kim S Thomas, Lucy Yardley, Miriam Santer, Ingrid Muller
Journal: British Journal of Dermatology (2022)

There is a lack of well-conducted randomized controlled trials evaluating the effectiveness of theory-based online interventions for eczema. To address these deficiencies, we previously developed and demonstrated the effectiveness of two online behavioural interventions: Eczema Care Online for parents/carers of children with eczema, and Eczema Care Online for young people with eczema.To explore the views and experiences of people who have used the Eczema Care Online interventions to provide insights into how the interventions worked and identify contextual factors that may impede users' engagement with the interventions.Qualitative semistructured interviews were conducted with 17 parents/carers of children with eczema and 17 young people with eczema. Participants were purposively sampled from two randomized controlled trials of the interventions and recruited from GP surgeries in England. Transcripts were analysed using inductive thematic analysis, and intervention modifications were identified using the person-based approach table of changes method.Both young people and parents/carers found the interventions easy to use, relatable and trustworthy, and perceived that they helped them to manage their eczema, thus suggesting that Eczema Care Online may be acceptable to its target groups. Our analysis suggested that the interventions may reduce eczema severity by facilitating empowerment among its users, specifically through improved understanding of, and confidence in, eczema management, reduced treatment concerns, and improved treatment adherence and management of irritants/triggers. Reading about the experiences of others with eczema helped people to feel 'normal' and less alone. Some (mainly young people) expressed firmly held negative beliefs about topical corticosteroids, views that were not influenced by the intervention. Minor improvements to the design and navigation of the Eczema Care Online interventions and content changes were identified and made, ready for wider implementation.People with eczema and their families can benefit from reliable information, specifically information on the best and safest ways to use their eczema treatments early in their eczema journey. Together, our findings from this study and the corresponding trials suggest wider implementation of Eczema Care Online (EczemaCareOnline.org.uk) is justified.
No association between physical activity and primary melanoma thickness in a cohort of Norwegian women
Authors: Flavie Perrier, Trude E Robsahm, Reza Ghiasvand, Kristin B Borch, Tonje Braaten, Elisabete Weiderpass, Corina S Rueegg, Adele C Green, Marit B Veierød
Journal: British Journal of Dermatology (2022)

‘In a cohort of Norwegian woman aged 30–75 years at recruitment, we investigated the association between physical activity and melanoma thickness at diagnosis, the most important prognostic factor for localized primary melanoma survival. We concluded that physical activity is unlikely to be associated with melanoma thickness.’
Are Janus kinase inhibitors an effective treatment for palmoplantar pustulosis? A critically appraised topic
Authors: David Gleeson, Jonathan N W N Barker, Francesca Capon, Andrew E Pink, Richard T Woolf, Catherine H Smith, Satveer K Mahil
Journal: British Journal of Dermatology (2022)

We carried out a critical appraisal of the literature to assess whether Janus kinase inhibitors are an effective treatment for palmoplantar pustulosis, a rare and debilitating form of psoraisis. Our appraisal identified case reports and case series of 16 patients who have been treated to good effect with tofacitinib, indicating this may be a promising therapeutic option. However, routine use of janus kinase inhibitors cannot be recommended outside the context of a clinical trial given the current low-quality of evidence available and the uncertain safety profile of Janus kinase inhibitors.
Efficacy and safety of switching psoriatic patients to bimekizumab: new evidence from clinical trials
Authors: Mario Valenti, Antonio Costanzo
Journal: British Journal of Dermatology (2022)

Journal Article Efficacy and safety of switching psoriatic patients to bimekizumab: new evidence from clinical trials Get access Mario Valenti, Mario Valenti Conceptualization, Writing - original draft Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy Search for other works by this author on: Oxford Academic Google Scholar Antonio Costanzo Antonio Costanzo Conceptualization, Supervision, Writing - review & editing Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy Correspondence: Antonio Costanzo. Email: antonio.costanzo@hunimed.eu Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 188, Issue 3, March 2023, Pages 316–317, https://doi.org/10.1093/bjd/ljac133 Published: 20 December 2022 Article history Received: 05 December 2022 Revision received: 08 December 2022 Accepted: 08 December 2022 Published: 20 December 2022 Corrected and typeset: 30 January 2023
Respiratory recovery trajectories after severe-to-critical COVID-19: a 1-year prospective multicentre study
Authors: Frédéric Schlemmer, Simon Valentin, Laurent Boyer, Anne Guillaumot, François Chabot, Clairelyne Dupin, Pierre Le Guen, Gwenael Lorillon, Anne Bergeron, Damien Basille, Julia Delomez, Claire Andrejak, Valentine Bonnefoy, Hélène Goussault, Jean-Baptiste Assié, Pascaline Choinier, Anne-Marie Ruppert, Jacques Cadranel, Maria Chiara Mennitti, Mehdi Roumila, Charlotte Colin, Sven Günther, Olivier Sanchez, Thomas Gille, Lucile Sésé, Yurdagul Uzunhan, Morgane Faure, Maxime Patout, Capucine Morelot-Panzini, Pierantonio Laveneziana, Maeva Zysman, Elodie Blanchard, Chantal Raherison-Semjen, Violaine Giraud, Etienne Giroux-Leprieur, Stéfanie Habib, Nicolas Roche, Anh Tuan Dinh-Xuan, Islem Sifaoui, Pierre-Yves Brillet, Camille Jung, Emmanuelle Boutin, Richard Layese, Florence Canoui-Poitrine, Bernard Maitre
Journal: European Respiratory Journal (2023)

Survivors of severe-to-critical coronavirus disease 2019 (COVID-19) may have functional impairment, radiological sequelae and persistent symptoms requiring prolonged follow-up. This pragmatic study aimed to describe their clinical follow-up and determine their respiratory recovery trajectories, and the factors that could influence them and their health-related quality of life.Adults hospitalised for severe-to-critical COVID-19 were evaluated at 3 months and up to 12 months post-hospital discharge in this prospective, multicentre, cohort study.Among 485 enrolled participants, 293 (60%) were reassessed at 6 months and 163 (35%) at 12 months; 89 (51%) and 47 (27%) of the 173 participants initially managed with standard oxygen were reassessed at 6 and 12 months, respectively. At 3 months, 34%, 70% and 56% of the participants had a restrictive lung defect, impaired diffusing capacity of the lung for carbon monoxide (DLCO) and significant radiological sequelae, respectively. During extended follow-up, both DLCO and forced vital capacity percentage predicted increased by means of +4 points at 6 months and +6 points at 12 months. Sex, body mass index, chronic respiratory disease, immunosuppression, pneumonia extent or corticosteroid use during acute COVID-19 and prolonged invasive mechanical ventilation (IMV) were associated with DLCO at 3 months, but not its trajectory thereafter. Among 475 (98%) patients with at least one chest computed tomography scan during follow-up, 196 (41%) had significant sequelae on their last images.Although pulmonary function and radiological abnormalities improved up to 1 year post-acute COVID-19, high percentages of severe-to-critical disease survivors, including a notable proportion of those managed with standard oxygen, had significant lung sequelae and residual symptoms justifying prolonged follow-up.
Immune Checkpoint Molecule TIGIT Regulates Kidney T Cell Functions and Contributes to AKI
Authors: Sanjeev Noel, Kyungho Lee, Sepideh Gharaie, Johanna T. Kurzhagen, Philip M. Pierorazio, Lois J. Arend, Vijay K. Kuchroo, Patrick Cahan, Hamid Rabb
Journal: Journal of the American Society of Nephrology (2023)

Significance Statement T cells mediate pathogenic and reparative processes during AKI, but the exact mechanisms regulating kidney T cell functions are unclear. This study identified upregulation of the novel immune checkpoint molecule, TIGIT, on mouse and human kidney T cells after AKI. TIGIT-expressing kidney T cells produced proinflammatory cytokines and had effector (EM) and central memory (CM) phenotypes. TIGIT-deficient mice had protection from both ischemic and nephrotoxic AKI. Single-cell RNA sequencing led to the discovery of possible downstream targets of TIGIT. TIGIT mediates AKI pathophysiology, is a promising novel target for AKI therapy, and is being increasingly studied in human cancer therapy trials. Background T cells play pathogenic and reparative roles during AKI. However, mechanisms regulating T cell responses are relatively unknown. We investigated the roles of the novel immune checkpoint molecule T cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) in kidney T cells and AKI outcomes. Methods TIGIT expression and functional effects were evaluated in mouse kidney T cells using RNA sequencing (RNA-Seq) and flow cytometry. TIGIT effect on AKI outcomes was studied with TIGIT knockout (TIGIT-KO) mice in ischemia reperfusion (IR) and cisplatin AKI models. Human kidney T cells from nephrectomy samples and single cell RNA sequencing (scRNA-Seq) data from the Kidney Precision Medicine Project were used to assess TIGIT's role in humans. Results RNA-Seq and flow cytometry analysis of mouse kidney CD4+ T cells revealed increased expression of TIGIT after IR injury. Ischemic injury also increased TIGIT expression in human kidney T cells, and TIGIT expression was restricted to T/natural killer cell subsets in patients with AKI. TIGIT-expressing kidney T cells in wild type (WT) mice had an effector/central memory phenotype and proinflammatory profile at baseline and post-IR. Kidney regulatory T cells were predominantly TIGIT+ and significantly reduced post-IR. TIGIT-KO mice had significantly reduced kidney injury after IR and nephrotoxic injury compared with WT mice. scRNA-Seq analysis showed enrichment of genes related to oxidative phosphorylation and mTORC1 signaling in Th17 cells from TIGIT-KO mice. Conclusions TIGIT expression increases in mouse and human kidney T cells during AKI, worsens AKI outcomes, and is a novel therapeutic target for AKI.
Membranous Nephropathy in Syphilis is Associated with Neuron-Derived Neurotrophic Factor
Authors: Sanjeev Sethi, Benjamin Madden, Marta Casal Moura, Raman Deep Singh, Samih H. Nasr, Jean Hou, Alok Sharma, Karl A. Nath, Ulrich Specks, Fernando C. Fervenza, Mark Haas
Journal: Journal of the American Society of Nephrology (2023)

Significance Statement Syphilis is a common worldwide sexually transmitted infection. Proteinuria may occur in patients with syphilis. Membranous nephropathy (MN) is the most common cause of proteinuria in syphilis. The target antigen of MN in syphilis is unknown. This study shows that MN in syphilis is associated with a novel target antigen called neuron-derived neurotrophic factor (NDNF). NDNF-associated MN has distinctive clinical and pathologic manifestations and NDNF appears to be the target antigen in syphilis-associated MN. Background Syphilis is a common sexually transmitted infection. Membranous nephropathy (MN) is a common cause of proteinuria in syphilis. The target antigen is not known in most cases of syphilis-associated MN. Methods We performed laser microdissection of glomeruli and mass spectrometry (MS/MS) in 250 cases (discovery cohort) of phospholipase A2 receptor–negative MN to identify novel target antigens. This was followed by immunohistochemistry/confocal microscopy to localize the target antigen along the glomerular basement membrane (GBM). Western blot analyses using IgG eluted from frozen biopsy tissue were performed to detect binding to target antigen. Results MS/MS studies of the discovery cohort revealed high total spectral counts of a novel protein, neuron-derived neurotrophic factor (NDNF), in three patients: one each with syphilis and hepatitis B, HIV (syphilis status not known), and lung tumor. Next, MS/MS studies of five cases of syphilis-MN (validation cohort) confirmed high total spectral counts of NDNF (average 45±20.4) in all (100%) cases. MS/MS of 14 cases of hepatitis B were negative for NDNF. All eight cases of NDNF-associated MN were negative for known MN antigens. Electron microscopy showed stage I MN in all cases, with superficial and hump-like deposits without GBM reaction. IgG1 was the dominant IgG subtype on MS/MS and immunofluorescence microscopy. Immunohistochemistry/confocal microscopy showed granular staining and colocalization of NDNF and IgG along GBM. Western blot analyses using eluate IgG of NDNF-MN showed binding to both nonreduced and reduced NDNF, while IgG eluate from phospholipase A2 receptor-MN showed no binding. Conclusion NDNF is a novel antigenic target in syphilis-associated MN.